Background. Predicting antimicrobial resistance in gram-negative bacteria (GNB) could balance the need for administering appropriate empiric antibiotics while also minimizing the use of clinically unwarranted broad-spectrum agents. Our objective was to develop a practical prediction rule able to identify patients with GNB infection at low risk for resistance to piperacillin-tazobactam (PT), cefepime (CE), and meropenem (ME).
Septic shock remains a deadly clinical entity across all types of intensive care units despite the availability of newer antimicrobials and aggressive resuscitation measures [1] . Bloodstream infection is the seventh leading cause of death in the United States, with a rising incidence due to emerging resistant bacterial strains [2, 3] . Mortality rates vary between 10% and 40%, and 25%-50% of all bloodstream infections are caused by gram-negative bacteria (GNB) [2, 4] . The administration of timely and adequate antimicrobial therapy has been repeatedly shown to improve patient outcomes in septic shock and is a cornerstone of the Surviving Sepsis guidelines [5, 6] . However, it is becoming more challenging to provide adequate empiric antimicrobial therapy due to the rising rates of resistance [7] [8] [9] [10] . This has resulted in greater administration of initial inadequate antibiotic therapy, which is associated with a greater risk of death [7, 8] . Moreover, rising rates of resistance have also contributed to the unwarranted empiric administration of broad-spectrum antibiotics, further promoting resistance emergence across microbial species.
Because piperacillin-tazobactam (PT), cefepime (CE), and meropenem (ME) represent the most common empiric antibiotic choices for the treatment of suspected GNB infection at our institution, we set out to identify risk factors for resistance to these 3 antimicrobials using a cohort of patients with bacteremia and sepsis or septic shock. To achieve this goal, we used both multivariable logistic regression (MLR) and recursive partitioning algorithms to obtain a clinical decision tree aimed at avoiding the administration of initial inadequate antibiotic therapy as well as the unnecessary administration of broad-spectrum agents. Moreover, the availability of such a decision model could aid in stratifying patients according to the need for double coverage or for change in antibiotic classes in the treatment of suspected GNB infections.
METHODS

Settings and Participants
The study was conducted at Barnes-Jewish Hospital, a 1300-bed academic referral center. The Washington University School of Medicine Institutional Review Board approved this investigation and waived the need for consent. All hospitalized adult patients with positive blood cultures for GNB between January 2008 and April 2015 were eligible for inclusion. Data were collected from the hospital's electronic health record system provided by the Center for Clinical Excellence, BJC Healthcare, Saint Louis, Missouri. This repository of electronic data includes diagnoses; Charlson and Acute Physiology and Chronic Health Evaluation (APACHE) II scores; laboratory, microbiology, and imaging results; and pharmacy data. It has been previously validated by manual data extraction with a concordance >95% for all the fields included. Variables that required a time window (eg, presence of central vein catheter (CVC) before antibiotics, mechanical ventilation initiated within 48 hours before or after the diagnosis of bacteremia) were also manually checked. Source of infection was determined based on concomitant positivity of blood cultures and other sterile cultures (eg, cerebrospinal fluid, tissue, and sputum) plus the descriptive diagnosis. When these criteria were not met, unknown source of infection was assigned.
The primary objective of this study was to determine predictors of resistance to PT, CE, and ME. To be included in the study patients had to be older than 18 years at the time of bacteremia and have septic shock or sepsis with associated organ dysfunction. We recorded comorbid conditions of interest; microbiology, laboratory, and imaging data; and markers of disease severity (APACHE score, septic shock, need for mechanical ventilation). The definitions used for this cohort have been reported elsewhere [11] . First, bacteremia was defined as the presence of ≥1 positive blood culture for a true pathogen. All episodes of bacteremia were recorded, but only the initial episode was used in the analyses. Patients with antimicrobial susceptibility data missing were excluded. Previous antibiotic use had to occur within 30 days of the index episode, and previous hospitalizations, in any BJC system hospital, within 90 days. Septic shock was defined as the need for vasoactive agents. Immunosuppression was defined as either AIDS or HIV infection, solid organ or bone marrow transplant, hematologic cancer, solid cancers treated with chemotherapy or radiation, long-term corticosteroid therapy (>10 mg/d), and treatment with other immunosuppressive drugs, such as biologics for rheumatologic disorders.
Microbiology and Pharmacology Methods
Antimicrobial susceptibility testing was standardized and was determined using the Phoenix BD Automated System (BD Diagnostics). Intermediate and dose-dependent susceptibilities were categorized as resistant. The minimum inhibitory concentration break points and interpretative criteria were up to date and concordant with the Clinical and Laboratory Standards Institute guidelines [12] . These followed the clinical break point changes for β-lactam antimicrobials.
From January 2002 through the present, Barnes-Jewish Hospital used an antibiotic control program. During this time, the use of azithromycin, ceftriaxone, CE, gentamicin, and vancomycin was unrestricted. However, initiation of treatment with intravenous ciprofloxacin, imipenem, ME, PT, ceftolozone-tazobactam, ceftazidime-avibactam, linezolid, or ceftaroline was restricted and required preauthorization.
Statistical Methods
We identified 4 groups of patients based on antimicrobial resistance: resistant to PT, resistant to CE, resistant to ME, and "nonresistant" controls. The 3 antimicrobial-resistant groups were not mutually exclusive, because some pathogens were resistant to >1 antibiotic of interest. Normally distributed continuous variables were recorded using means and standard deviations. Otherwise we recorded medians and interquartile ranges.
All candidate variables with P values <.10 in univariable analyses were considered for inclusion in the multivariable models. The final models were developed using stepwise logistic regression with backward elimination at a significance level of .05. Goodness of fit was evaluated using the Hosmer-Lemeshow test.
Decision tree analyses were performed using the Stata algorithm CHAID (χ 2 Automatic Interaction Detection), as described elsewhere [13, 14] . In brief, CHAID is a recursive-partitioning algorithm that uses logistic regression to calculate χ 2 values.
Continuous variables are divided into categories and treated as ordinal variables. If the categories are significantly different (P < .05), in terms of the outcome of interest (resistance to a specific antibiotic), they will be retained as such. If not, they are merged, and the algorithm repeats until it keeps only the significant categories for all the variables. Once all categories have been merged, CHAID conducts a χ 2 association test of each splitting variable for the response variable and records a Bonferroni-adjusted P value. If the smallest P value is less than the user-specified threshold (.05), the data are split, the splitting variable becomes the first node, and the algorithm reinitiates with the remaining variables. The process stops once the minimum cluster size of 100 was not met for potential splits, the parent node was <200, or a cluster was homogenous in terms of the response variable.
Our algorithms looked at all the study variables, including date of bacteremia, as potential predictors of resistance to PT, CE, and ME. The percentages in the final nodes represent the probability of antibiotic resistance within that group. We defined low probability for resistance as resistance in the terminal node of <10%, intermediate probability as resistance of 10%-30% and high probability as resistance of >30% [15] . Discrimination for each of the decision trees and MLR models was evaluated using C statistics, and Brier scores were used for calibration.
Over the 7 years, a total of 1618 consecutive patients met our inclusion criteria. Approximately half had exposure to the healthcare system, as reflected by previous hospitalization and previous antibiotic use (Table 1) . Of the isolates, 462 (28.6%) of the isolates were resistant to PT, 352 (21.8%) to CE, and 138 (8.5%) to ME; 153 (9.5%) isolates were resistant to both PT and CE. and 106 (6.6%) were resistant to all 3 drugs of interest.
Patients with resistant isolates were more likely to be admitted from a nursing home, require hemodialysis, have a CVC, have longer hospital stays before bacteremia, and be acutely sicker at diagnosis (higher rates of mechanical ventilation and septic shock) ( Table 1) .
Pseudomonas, Acinetobacter, and Stenotrophomonas spp. accounted for the majority of isolates resistant to ME, whereas Enterobacter spp. and Acinetobacter spp., respectively, were the pathogens most commonly resistant to PT and CE. Serratia spp. also accounted for a significant number of the PT-resistant isolates. Pneumonia was the main source of infection for all 3 resistant groups.
Multivariable analyses identified common risk factors for all 3 groups: nursing home residence, transfer from an outside hospital and use of antibiotics within 30 days before the index admission (Tables 2-4 ). Resistance to ME was also associated with infections caused by Pseudomonas and Acinetobacter spp. Likewise, the source of infection seemed to matter: central nervous system and CVC infections were associated with resistance to PT, and an unknown source of infection was protective against ME resistance. The MLR models predicting resistance to PT and CE had moderate area under the receiver operating characteristic (AUROC) curves of 0.68 and 0.63, respectively, whereas the MLR model associated with ME resistance was more robust, with an AUROC curve of 0.83. The clinical decision trees were useful in identifying patient clusters with low probability of bacteremia caused by pathogens resistant to PT, CE, and ME (Figures 1-3 ). Resistance to ME was very unlikely (1.5% and 3.8%) in 2 clusters totaling 974 patients (60% of the entire cohort). Cluster 1 included patients without a CVC in whom no Pseudomonas or Acinetobacter spp. were isolated, and cluster 2 included patients with a CVC and no lung source of infection, also without Pseudomonas or Acinetobacter spp. infection. In all, 28.9% of patients had a high probability of resistance to PT; admission from a nursing home and having had a CVC was associated with the highest probability (47.2%) of resistance to PT. The likelihood of CE resistance was highest (37.6%) for patients in septic shock requiring mechanical ventilation and having had a CVC. The AUROC curve for the clinical decision tree analyses was similar to that for the MLR models: 0.67, 0.61, and 0.80 for resistance to PT, CE, and ME, respectively.
Considering the probability of resistance to the 2 remaining drugs conditional on a high probability of resistance to the first drug, only 1 cluster with high resistance to PT (cluster 3) exhibited low resistance to ME (7.2%) ( Table 5 ). All other high-resistance clusters demonstrated intermediate to high levels of resistance to the other antimicrobials of interest. 
Sensitivity Analyses for the Clinical Decision Trees
For each antibiotic, we repeated the CHAID algorithm in the subset of patients who lacked the first 2 factors for resistance: mechanical ventilation and any surgery for resistance to CE, identification of Acinetobacter or Pseudomonas spp. and presence of a CVC for resistance to ME, and presence of a CVC and prior use of antibiotics for resistance to PT. All trees failed to converge consistent with truncation at node 1 of the original trees. When the sizes of the parent and terminal nodes were changed, the clinical decision trees remained the same for CE and PT. Five more branches were added to the ME tree but without a significant change in the predictive discrimination (C statistic, 0.84; P = .36).
DISCUSSION
Using a relatively simple decision tree built on readily available variables, resistance to ME can be ruled out in patients with GNB bacteremia not caused by Pseudomonas or Acinetobacter spp. For PT and CE resistance, clinical decision trees were able to separate out from the entire cohort septic patients at low risk for resistance. The decision tree analysis was also able to identify the patient clusters having a high risk (>30%) of resistance to PT, CE, or ME. We also found good overall agreement between the accuracies of the MLR models and the decision tree analyses for predicting antibiotic resistance.
Even though the 3 drugs of interest are all β-lactam antibiotics and share common pathways of resistance, significant differences exist. AmpC β-lactamases produced by species like Enterobacter and Serratia will hydrolyze cephalosporins and not be inhibited by β-lactamase inhibitors. By having better permeability, CE retains more of its effect on the β-lactamase producing microbes, with 1 study showing outcomes comparable to those of ME [16] . Some of the newer plasmid-encoded extended-spectrum β-lactamases (ESBLs) can be inactivated by β-lactamase inhibitors, such as tazobactam, but these organisms usually harbor other resistance pathways, including loss of porins and hyperproduction of AmpC β-lactamases. Although carbapenemases remain relatively infrequent in the United States, other resistance mechanisms-for example, efflux pumps and porin modifications by Pseudomonas spp., can increase resistance to this antimicrobial class as well. These differences in acquiring resistance to specific antibiotics echo clinically in our study findings that overall susceptibility to PT had the lowest rates, whereas Pseudomonas and Acinetobacter spp. were directly associated with resistance to ME.
Monitoring of resistance patterns and antibiotic usage patterns in the United States reveals several interesting observations. First, Acinetobacter spp. isolated from blood or cerebrospinal fluid now have resistance rates >20% to all common antibiotics except for polymixins. Resistance to all classes of antibiotics is >10% in cases of Pseuodmonas infection, while Klebsiella spp. are following the same trend, with only carbapenems remaining active against >90% of these isolates [17] . A large study that surveyed 101 intensive care units in the United States and Europe found that susceptibility to ME was only 73% for Pseuodmonas and 43% for Acinetobacter spp. [18] . Similar findings were reported in CVC-associated bloodstream infections, in which more than half of the Acinetobater isolates were resistant to carbapenems and more than a quarter of the Pseudomonas spp. were resistant to PT and carbapenems [19] .
The risk factors for resistance observed in our study are consistent with those identified in previous reports and partially overlap between PT, CE, and ME, including prior antibiotic exposure and nursing home residence [20] [21] [22] . Even though not significant in all 3 of the MLR models we developed, the presence of CVCs was one of the principal branching nodes in our clinical decision tree models. The risk factors we identified do not discriminate between individual multidrug-resistant GNB, and they have also been associated with infections due to methicillin-resistant Staphylococcus aureus [21, 23] . Previous studies have focused on predicting the causative bacterial species associated with sepsis and septic shock, including methicillin-resistant S. aureus, Enterobacteriaceae, Pseudomonas spp., ESBL-producing Escherichia coli, and Klebsiella spp. [9, 21, [24] [25] [26] [27] . We believed that a tool able to predict antimicrobial resistance would be more relevant Figure 3 . Clinical decision tree to predict the likelihood that gram-negative bacteria are resistant to meropenem (ME). For each node, branches oriented to the right represent the presence of that node's risk factor, and branches to the left represent its absence. The terminal node sizes from left (cluster for no Pseudomonas or Acinetobacter spp. isolated and no central vein catheter [CVC] ) to right (cluster for Pseudomonas and Acinetobacter isolated and previous use of antibiotics) were 471, 503, 210, 114, and 177 patients, respectively. Percentages reflect the likelihood of isolating a microbe resistant to ME in each terminal node. The Brier score was 0.065. CHAID, χ 2 Automatic Interaction Detection. .1% probability of resistance to PT), PT cluster 7 (233 patients with 47.2% probability of resistance to PT), CE cluster 5 (173 patients with 37.6% probability of resistance to CE), and ME cluster 5 (177 patients with 32.2% probability of resistance to ME).
to practicing clinicians. We focused on the 3 most common empiric antibiotics used when infection due to GNB is suspected as the cause of sepsis. A prior study examining fluoroquinolone resistance in GNB bacteremia developed an integer score based on male sex, diabetes, nursing home residence, prior fluoroquinolone use, and prior outpatient procedures to predict the presence of resistance [28] . No other prediction models have previously been developed for resistance to PT, CE, or ME to our knowledge. Rapid microbiology diagnostic methods will help to guide appropriate use of antibiotics in the future, but until these methods become widely available, other strategies are needed [29] . Automated electronic queries can identify patients at risk of initial inadequate antibiotic therapy, and computer-generated antibiotic recommendations may improve antibiotic utilization and reduce length of stay [30] [31] [32] . Using electronic health records, prediction models like the ones we describe, developed according to local case mix. can be validated locally to determine the probability of infections caused by resistant GNB. MLR analyses allow risk factors associated with antibiotic resistance to be described as odds ratios, but these do not translate readily into relative risks. Clinical decision trees potentially offer a more practical and user-friendly approach for applying such data at the bedside. A recent study used recursive partitioning methods to identify patients at risk for ESBL E. coli or Klebsiella spp. bacteremia [25] . The cluster characterized by the absence of the 2 main risk factors (no recent history of colonization or infection with an ESBL microbe and no recent hospitalization in a highly endemic area) had a robust size, but all other terminal nodes had very few patients to allow meaningful clinical generalization. We set the dimensions of the final nodes in our decision trees so they would remain relevant in clinical practice.
Several limitations of our study should be noted. This was a single-center case control retrospective study based mainly on computer-generated queries of electronic health records. Some risk factors may not vary across institutions, but their relative weight and interactions probably do. Our models will need to be validated in different institutions. We probably had inadequate reporting of some risk factors, such as previous antibiotic exposure, because we could not assess records from hospitals outside our system. We also were unable to account for the level of antimicrobial resistance in our community setting. Community-acquired cases of ESBL microbes have increasingly been described [33, 34] . Finally, it is possible that risk factors for antibiotic resistance may vary temporally owing to changing antimicrobial practices, stewardship interventions, and pathogen prevalence, but date of bacteremia did not affect the MLR and CHAID trees' results. Our decision analyses focused on GNB bacteremia but the Gram stain results may not be readily available in certain hospitals where 24-hour laboratory services are lacking.
In summary, we provide a decision tree method to help differentiate patients with low, moderate, and high probabilities of antimicrobial resistance to the antibiotics most commonly used for the empiric treatment of GNB sepsis and septic shock [35] . This method can be applied relatively easily to derive local decision trees. These findings provide a framework for how empiric antibiotics can be tailored according to decision tree patient clusters. Patients at low risk for resistance to PT or CE can be treated with those antibiotics. Patients at intermediate risk should receive double coverage, possibly with an aminoglycoside, to ensure appropriate coverage. For those at high risk of resistance to PT or CE, consideration should be given to prescribing ME or double coverage with ME and a second agent. Patients at high risk of ME resistance should probably receive either 2 different classes of agents targeting GNB or a new broader-spectrum antibiotic. Combining user-friendly clinical decision trees and MLR models may offer the best opportunities for hospitals to derive local models to help with antimicrobial prescription. 
